Mycotoxin Control in Supplements: Part 111 Requirements
Connect ingredient risk, supplier evidence, representative sampling and laboratory results to documented quality decisions for dietary supplements.

On this page · 11 sections
- 1What mycotoxin control covers—and what it does not
- 2US supplement specifications: the binding Part 111 framework
- 3Assess risk by ingredient, material form and supply history
- 4Supplier-side prevention: drying, storage and shipment evidence
- 5Incoming verification: representative samples, testing and conditional COA reliance
- 6Connect component evidence to in-process and finished-batch controls
- 7Worked decisions: inconclusive results, split shipments and blend estimates
- 8Build a traceable evidence model across receiving, laboratories and quality
- 9Common failure modes: evidence gaps that resemble acceptable results
- 10Recover from exceptions without losing the original evidence
- 11Implementation and review checklist: test the whole decision chain
How does Mycotoxin Control (Supplements) apply to your shop floor?
Pick your industry and scale — Ask V5 rewrites the definition in your context, gives a worked example, and shows what V5 does on day one.
01What mycotoxin control covers—and what it does not
Mycotoxin control in supplements is the management of fungal-toxin contamination risk in dietary ingredients and finished dietary supplements through prevention, manufacturer-set specifications, representative sampling, verification and documented disposition decisions. This is an operational description, not a legal definition or a prescribed universal control programme.
| Term | Primary question | Relevant evidence | Boundary |
|---|---|---|---|
| Mycotoxin control | Is fungal-toxin risk controlled? | Prevention records, specifications, sampling records, analytical results, disposition | Programme, not an isolated test |
| Microbial control | What microbial contamination is present or controlled? | Microbial counts, organism-specific results, hygiene records | A microbial count does not report mycotoxin concentration |
| Botanical identity testing | Is this the intended botanical ingredient? | Identity test or examination results | Identity does not establish toxin concentration |
| Broader contaminant control | Which contamination hazards need control? | Hazard assessment and contaminant-specific evidence | Mycotoxins are one hazard group within this wider activity |
| COA review | What does the supplier report for this lot? | Certificate of analysis and supporting lot references | Evidence-document review, not a separate hazard-control system |
The programme commonly spans supplier prevention, incoming-component decisions, relevant process controls and finished-batch evidence. A useful boundary is the decision being supported: whether to accept an ingredient, continue processing or disposition a finished batch. No single certificate describes that entire chain.
Keep measured mycotoxin concentration, visible material condition and supplier confidence as separate observations. Appearance and supplier history can inform scrutiny, but neither is interchangeable with a toxin result or its acceptance criterion. Use supplier risk management to organise supplier-level evidence without treating it as a lot-specific measurement.
For the legal obligations, continue to the US supplement specification framework below, covered in the Part 111 framework; for selecting hazards and controls, see the ingredient-specific risk assessment discussed later in this article.
02US supplement specifications: the binding Part 111 framework
For US dietary supplement components, 21 CFR 111.70(b)(3) requires manufacturers to establish limits on contamination that may adulterate or lead to adulteration of the finished supplement.
For US dietary supplements, 21 CFR 111.70(e) requires finished-product specifications that include limits on contamination that may adulterate or lead to adulteration of the finished batch. These belong in the manufacturer's finished-product specifications.
For US dietary supplements, 21 CFR 111.70(a) requires specifications at manufacturing points, steps or stages where control is necessary to ensure supplement quality.
Map the product and market before selecting criteria
| Market and product | Specification level | Binding provision | Separate assessment needed |
|---|---|---|---|
| US dietary supplement components | Component contamination limits | 111.70(b)(3) | Ingredient-specific contamination hazards |
| US dietary supplements during manufacture | Points, steps or stages needing control | 111.70(a) | Where manufacturing control is necessary |
| US finished dietary supplements | Finished-product contamination limits | 111.70(e) | Criteria for the finished formulation |
| Conventional food, animal feed or non-US products | Separate product-and-market assessment | Determine separately | Classification, destination and applicability of any commodity criterion |
As a regulatory-scoping practice, assess conventional food, animal feed and non-US products separately. Do not transfer a commodity criterion into a supplement specification merely because the ingredient name matches. For mycotoxin control, document the basis for the selected analytes and acceptance criteria rather than treating a familiar panel or threshold as universal. The broader Part 111 framework provides context for the supplement assessment.
Make the specification usable—and identify its authority
A practical specification record commonly identifies the ingredient or product; analyte or defined analyte group; acceptance criterion; units; reporting basis; analytical suitability; rationale; revision; and approver. Keeping units and reporting basis beside the criterion helps reviewers compare the laboratory result with the intended specification. These are documentation conventions, not an additional statutory field list.
Keep source classifications explicit: the cited provisions are binding US supplement regulations; official guidance recommendations are a separate category; the record design above is industry practice. For generic software support, treat data storage and routing as administrative functions, not evidence of compliance. Keep human review and approval distinct from system status, and do not label a recommended practice as a regulatory requirement.
03Assess risk by ingredient, material form and supply history
A practical mycotoxin assessment starts with the ingredient as purchased, not simply its botanical category. This is an industry-practice approach to selecting hazards and controls, not a universal ranking of ingredient categories. Consider these inputs together within supplier risk management:
- Identity and plant part: identify the botanical and the part used; distinguish seed- or grain-derived ingredients rather than treating all plant materials alike.
- Material form: distinguish whole material, milled material and extracts. For an extract, consider the starting material and processing history rather than assuming the finished form resolves the hazard.
- Supply history: consider origin, harvest conditions, drying and storage history, transport conditions and relevant supplier results. Note gaps or uncertainty rather than treating missing information as reassuring.
Aflatoxins and ochratoxin A are examples of candidate hazards for ingredient-specific assessment. They are not presented here as a comprehensive list of regulated supplement mycotoxins or a mandatory analytical panel for every botanical. Record the rationale for including or excluding candidate hazards in the assessment.
Separate hazard relevance from analytical coverage. A relevant toxin may be absent from a laboratory’s panel; even a panel naming that toxin may have reporting capability unsuitable for the manufacturer’s specification. Compare the actual analyte coverage and reporting capability with the intended decision, rather than relying on the panel name.
Record what would trigger reconsideration: a material-form change, a different origin, changed handling conditions or new supplier information. Use the findings to target supplier-side prevention, discussed next, including questions about unresolved handling risks, rather than treating laboratory testing as the entire control programme.
04Supplier-side prevention: drying, storage and shipment evidence
In industry practice, supplier-side prevention reviews examine how the specific ingredient is dried, protected from moisture, stored, segregated and transported. A useful supplier oversight review asks for records linked to the material, lot and handling stage—not just a general questionnaire describing the supplier’s usual arrangements.
- Drying: ask which procedure applied, how completion was assessed and whether deviations occurred.
- Storage: review recorded conditions, moisture protection and any movement between storage locations.
- Packaging and segregation: ask how damaged containers and suspect material were identified, separated and handled.
- Transport: connect dispatch and shipment records to the received lot; examine evidence of moisture exposure or packaging damage during transfer.
Keep prevention evidence separate from acceptance evidence. Handling records explain how risk was managed; the receiving decision uses the applicable specification and its associated verification evidence. Neither supplier reputation nor a satisfactory handling narrative substitutes for a documented acceptance decision.
Practical escalation triggers include wet or damaged packaging, unexplained storage changes, missing lot traceability and inconsistent supplier records. Record the receiving discrepancy, identify the affected receipt and assign a quality reviewer to assess the concern and determine what additional evidence is appropriate. Set triggers against material risks and established procedures rather than universal moisture, temperature or storage-duration values.
Practical workflow: supplier prevention records → receiving inspection and discrepancy review → sampling → verification against the applicable specification → documented human disposition decision. Carry unresolved handling concerns forward with the receipt’s evidence.
- Assess riskConnect material characteristics, handling history and relevant hazards.
- Set specificationsDocument analytes, criteria, units and the approved revision.
- Review supplierConnect qualification evidence, handling records and COA scope.
- Identify receiptDistinguish shipment, supplier lot and internal receipt.
- Collect samplesPreserve representative sampling records and sample identity.
- Evaluate evidenceResolve scope, reporting capability and specification comparisons.
- Approve dispositionRecord the human decision and downstream batch links.
05Incoming verification: representative samples, testing and conditional COA reliance
For US dietary supplement components received from suppliers, 21 CFR 111.80(a) requires representative samples of each unique shipment and each unique lot within each shipment. Sampling establishes which received material the evidence represents; choosing the verification evidence is a separate decision. In practice, representative sampling is not synonymous with ordering an identical full mycotoxin panel for every receipt.
For US dietary supplement components, 21 CFR 111.75(a)(2) requires confirming the identity of other components and determining whether other applicable component specifications established under 111.70(b)—such as contamination limits, including selected mycotoxin specifications—are met, through appropriate tests or examinations or conditional reliance on a supplier COA. This is separate from dietary-ingredient identity testing, which 21 CFR 111.75(a)(1)(i) addresses independently, subject to a petition-based exemption under 111.75(a)(1)(ii). Organise the supplier COA verification programme around the contamination specification being evaluated, rather than treating possession of a certificate as the decision or extending COA reliance to dietary-ingredient identity verification.
Binding conditions for supplier COA reliance
- For US dietary supplement components, 111.75(a)(2)(ii)(A) requires first qualifying the supplier by establishing COA reliability through confirmation of the supplier’s test or examination results.
- For US dietary supplement components, 111.75(a)(2)(ii)(B) requires the COA to include method descriptions, test or examination limits, and actual results.
- For US dietary supplement components, 111.75(a)(2)(ii)(C) requires maintaining documentation of how the supplier was qualified.
- For US dietary supplement components, 111.75(a)(2)(ii)(D) requires periodically reconfirming the supplier’s COA.
- For US dietary supplement components, 111.75(a)(2)(ii)(E) requires quality control personnel to review and approve the documented basis for supplier qualification and requalification.
Practical sampling-to-result chain
A useful receiving workflow connects the following records without substituting one for another:
- Identify the shipment and supplier lot, and link them to the internal receipt and component identifier.
- Follow the applicable sampling procedure; record the sampled material and preserve sample identity through transfer to the laboratory.
- Communicate the ingredient matrix, material form and requested analytes so the laboratory understands the intended scope.
- Compare reported results with the applicable specification using approved units and reporting basis; resolve mismatches before interpreting conformity.
- Link the result or relied-on COA to the receipt, specification revision and documented review decision.
Consistent material master data helps prevent a result for one ingredient form from being assigned to another. This workflow is industry practice for preserving interpretability, not an additional prescribed toxin panel.
06Connect component evidence to in-process and finished-batch controls
A practical mycotoxin control argument connects the ingredient actually used, the conditions encountered during manufacture and the evidence selected for the finished batch. An incoming result is one part of that argument.
For US dietary supplements under 21 CFR 111.75(b), manufacturers must monitor in-process points, steps or stages where control is necessary to ensure finished-batch quality.
For US dietary supplements under 21 CFR 111.70(c)(2), manufacturers must document the basis for why meeting in-process specifications together with component specifications helps ensure specifications are met. For US dietary supplements under 21 CFR 111.70(c)(3), quality control personnel must review and approve that documentation.
For US dietary supplements, 21 CFR 111.80(c) addresses representative samples from a subset of finished batches identified through a sound statistical sampling plan, or otherwise every finished batch. For US dietary supplements under 21 CFR 111.75(c)(2), manufacturers must conduct appropriate tests or examinations against the specifications selected under paragraph (c)(1).
As practical implementation, build a product- and process-specific evidence chain:
- Trace each ingredient lot and its mycotoxin evidence to the manufacturing batch in the batch production record.
- Connect relevant process observations to the rationale behind the in-process specifications, explaining why those controls support the intended conclusion.
- Identify the selected finished-batch evidence and the finished-product specifications it evaluates; distinguish measured results from conclusions supported by the combined evidence.
The review question is whether the linked evidence supports this particular product after its actual processing—not whether an acceptable incoming result can simply be carried forward through every transformation.
07Worked decisions: inconclusive results, split shipments and blend estimates
Below quantitation is not necessarily below specification
Assume a botanical powder has an approved analyte specification in µg/kg. Sample identity and reporting basis match, but the laboratory reports below quantitation with a quantitation limit above the acceptance limit. This report leaves concentrations on either side of the acceptance limit possible; it does not establish conformity or demonstrate an exceedance.
Ask the laboratory to clarify the reporting qualifier and whether its underlying data support comparison with the acceptance limit. If not, seek suitable analysis capable of resolving that comparison. Decision owner: quality, supported by the laboratory. Unresolved question: does the concentration meet the approved specification? Evidence needed: a clarified report or suitable analytical result. The quality decision remains pending.
Same supplier lot, separate receiving evidence
Assume separate shipments carry the same supplier lot identifier and share a COA. The earlier receipt has complete evidence; the later receipt lacks its own sampling record. Apply the incoming-lot verification framework covered earlier in this article: retain separate receipt identities within the lot pedigree, then locate the later shipment’s sampling evidence. Neither the shared COA nor the earlier record demonstrates that later receiving activity occurred.
Decision owner: quality, with receiving personnel. Unresolved question: was the later shipment representatively sampled? Evidence needed: its attributable sampling record, or documented resolution of the missing activity—not a copied earlier receipt record.
Blend estimates describe contribution, not acceptance
Assume ingredient masses are in kg, concentrations are in µg/kg, reporting bases match, and mixing is complete and uniform, without toxin removal or formation. Each ingredient mass multiplied by its concentration gives toxin mass in µg. Sum those toxin masses and divide by total blend mass in kg to estimate blend concentration in µg/kg.
Keep this estimate separate from component acceptance and representative finished-batch evidence; it is not an instruction to dilute a nonconforming ingredient into acceptability. Decision owner: quality, supported by formulation and laboratory personnel. Unresolved question: do the inputs and mixing assumption describe the actual batch? Evidence needed: traceable masses, interpretable concentrations and appropriate batch evidence, including blend-uniformity sampling where relevant.
08Build a traceable evidence model across receiving, laboratories and quality
A practical mycotoxin evidence model connects each disposition decision to its inputs and approved criteria. The structure below is a suggested implementation, not a list of statutory database fields. Use linked records rather than a single attachment folder or an unexplained acceptance flag.
- Ingredient context: material identity and form, risk assessment reference, applicable specification revision, supplier qualification record and supplier certificate of analysis (COA) reference.
- Receipt and sample: purchasing reference, supplier identity, shipment identifier, supplier-lot identifier, internal receipt identifier and sample identifier. Map each sample to its particular receipt and supplier lot.
- Results and decision: analytical records, comparison against the referenced specification, ingredient-to-manufacturing-batch links, and the human disposition record with reviewer, date and rationale.
At the receiving-to-laboratory handoff, pass the receipt and sample identifiers with the requested analytes. At the laboratory-to-quality handoff, carry analyte identity, result qualifier, units, reporting basis, analytical limit and its type, and method reference alongside the result. These are useful design considerations for MES to LIMS integration: preserve result meaning rather than silently reducing the payload to a pass status. Route unmatched identifiers or incompatible reporting bases for review rather than guessing the association.
For data integrity by design, preserve original results and link controlled corrections to their predecessors, recording who changed what and why. Retain the specification version used for each decision. Keep supplier COA results distinguishable from independent laboratory results, even for the same lot and analyte. Ingredient-to-batch links then help investigators identify which manufacturing decisions used that evidence.
Generic software support may organise records and comparisons. In this operating model, authorised humans review evidence and approve disposition or batch release. A database status neither certifies compliance nor authorises automatic quality release.
Ingredient Risk
Explains hazard selection for the material.
- ingredient_id
- material_form
- hazard_rationale
- assessment_revision
Approved Specification
Defines the comparison criteria and basis.
- specification_revision_id
- analyte
- acceptance_limit
- result_unit
- reporting_basis
Receipt and Sample
Connects shipment identity with supplier evidence.
- receipt_id
- shipment_id
- supplier_lot_id
- sample_id
- sampling_plan_id
- coa_id
- supplier_qualification_id
Analytical Result
Preserves analytical meaning and source traceability.
- result_id
- sample_id
- analyte
- result_value
- result_qualifier
- result_unit
- reporting_basis
- quantitation_limit
- method_id
Quality Disposition
Links reviewed evidence to authorised decisions.
- disposition_id
- receipt_id
- specification_revision_id
- evidence_refs
- affected_batch_ids
- reviewer_id
- decision
- approval_timestamp
09Common failure modes: evidence gaps that resemble acceptable results
A plausible mycotoxin result can still support an unreliable receiving decision. The following practical controls address traceability and interpretation failures; they are not a separate regulatory checklist.
| Failure mode | Why the decision becomes unreliable | Practical control | Review evidence |
|---|---|---|---|
| Sample linked to the wrong receipt | The result describes material other than the receipt being evaluated. | Reconcile receipt, supplier lot, shipment and sample identifiers before accepting the link. | Matched receiving and sampling records, with reviewer identity and resolution of discrepancies. |
| Partial-panel report imported as a complete panel | A report-level status conceals unreported analytes. | Check completeness analyte by analyte against the selected panel. | Expected-versus-reported analyte comparison, including missing entries and reviewer disposition. |
| Result compared with an obsolete specification | Acceptance reflects a superseded criterion rather than the applicable specification. | Select the specification revision explicitly and record its applicability. | Revision identifier, applicability rationale and retained comparison reviewed by quality. |
| Corrected COA overwrites its predecessor | The original basis for an earlier decision disappears. | Preserve original and corrected records; link the correction and reassess affected decisions. | Both COA versions, correction reason, receipt dates and documented impact review. |
Classify exceptions separately: missing data asks what evidence is absent; invalid analysis asks why the analysis cannot support interpretation; inconclusive reporting asks what remains unresolved; an out-of-specification result asks why the applicable criterion was not met. Any category can block a decision. Use the worked cases above for analytical ambiguity rather than treating every exception as a retest request.
Where documentary gaps began before receipt, connect the investigation to supplier-side prevention evidence, including the original handling and shipment records.
10Recover from exceptions without losing the original evidence
For US dietary supplements under 21 CFR 111.75(i), manufacturers must establish corrective action plans for use when an established specification is not met. The practical workflow below supports investigation and recovery; it is not a prescribed sequence in that provision.
- Preserve the original laboratory report and its connection to the sample. Identify affected receipts and batches, and maintain the appropriate material status while the issue remains unresolved.
- Frame the investigation question: does the uncertainty concern the material, sampling, laboratory work or record transfer? Obtain relevant evidence and document the authorised disposition through the out-of-specification handling workflow.
- Tie additional testing to a defined question. Retain earlier results and explain how subsequent evidence affects the decision rather than silently replacing an inconvenient result.
Treat an integration failure separately from a material-quality conclusion. For a missing, duplicated or rejected result message, reconcile the source report, identifiers and import history. In MES–QMS integration, a successful retransmission establishes data transfer, not analytical conformity.
Close the investigation with the disposition rationale, affected-record references, responsible reviewer and any supplier or control changes. Use the failure-mode controls discussed earlier in this article to identify whether recurrence prevention concerns sampling, laboratory communication, supplier evidence or data handling.
11Implementation and review checklist: test the whole decision chain
Use these practical review prompts to test readiness; they add no legal requirements to the binding framework covered above.
- Ingredient-risk rationale: Does the assessment explain hazard selection for the ingredient and material form?
- Specification and reporting basis: Can reviewers identify the approved version, analytes, units and interpretation basis?
- Supplier qualification: Is supporting evidence accessible through supplier risk management records?
- Shipment and sample identity: Do receiving, sampling and laboratory identifiers resolve to the same material?
- Laboratory scope and capability: Does the analytical arrangement address the selected analytes and matrix?
- In-process and finished-batch rationale: Is the connection between control stages documented?
- Exception handling: Are unresolved questions visible, assigned and prevented from disappearing during handoffs?
- Traceability: Can records connect the original result, revisions, assessment and disposition?
- Named decision authority: Is a person assigned to review evidence and approve the disposition?
Challenge the workflow with a missing analyte, an unmatched shipment identifier, a result assessed against an outdated specification and a corrected laboratory report. Use audit trail review to ask: can a reviewer reconstruct the outcome from retained records without undocumented explanations?
Trigger review when ingredients, supplier sites, analytical arrangements or specifications change, or when recurring exceptions or emerging risk information warrant reassessment. Assign owners and response expectations within site procedures and change control, rather than imposing a universal calendar interval.
Reading path: control definition → matrix assessment → verification evidence.
Frequently asked questions
Q.What information should a contract laboratory receive before performing incoming-lot mycotoxin analysis?+
A practical laboratory brief identifies the botanical species, plant part, ingredient form, supplier lot, sample identifier, and requested toxins, including how any reported total is defined. Include the applicable specification, reporting units, moisture basis, and reporting sensitivity needed for the acceptance decision. Describe sampling and sample preparation, and ask the laboratory to confirm suitability for the matrix before analysis. These details also provide useful fields for a controlled laboratory data exchange.
Q.How should a dry-weight laboratory result be compared with an [as-received specification](/glossary/material-master-data)?+
Common analytical practice is to align the reporting basis before comparing concentrations. Assuming moisture is expressed as a fraction of as-received mass, multiply the dry-weight concentration by the dry-solids fraction to obtain the as-received concentration. Keep the concentration units unchanged. Use moisture data representative of the tested material, not a nominal supplier value. Record the moisture result and conversion alongside the relevant lot attributes, and resolve ambiguous laboratory reporting conventions before making the comparison.
Q.What should be reassessed when a [botanical ingredient changes](/glossary/change-control) from whole material to an extract?+
A practical reassessment covers the starting botanical, extraction solvent, process conditions, concentration basis, carriers, and subsequent handling. Do not assume the whole-material result predicts the extract result: investigate whether toxins transfer into, remain outside, or become concentrated in the extract. Revisit the sampling approach, analytical recovery, matrix interference, and specification rationale for the new form. The resulting control strategy should connect evidence about the extraction process with testing suitable for the actual purchased ingredient.
Q.How should a manufacturer evaluate a toxin that is not included in its routine panel?+
A practical assessment starts with why the toxin is plausible for that ingredient: botanical source, growing region, storage conditions, supplier history, or credible occurrence reports. Document the question in the quality risk register, then assess exposure relevance and whether a laboratory can measure the toxin suitably in that matrix. Targeted exploratory testing may help resolve uncertainty. Record the rationale for adding it, monitoring it separately, or excluding it; a negative routine panel does not answer an unmeasured-toxin question.
Q.What additional traceability matters when a laboratory subcontracts part of the analysis?+
Common laboratory oversight practice is to identify the performing laboratory, the work transferred, and the sample identifiers used at each handoff. Retain dispatch and receipt records, sample condition, preparation history, and links between the subcontractor's report and the issuing laboratory's final report. Check who performed extraction, measurement, calculations, and technical review, especially where responsibilities are split. Connect these records to the ingredient's lot pedigree so a later correction can be traced to the affected result.
Q.How should a new supplier manufacturing site affect the existing [supplier-control assessment](/glossary/supplier-qualification-audit-supplement)?+
A site-specific supplier oversight review commonly examines whether the evidence supporting the existing relationship remains applicable. Compare raw-material sourcing, drying and storage operations, equipment, environmental conditions, sampling arrangements, and laboratory services at the new location. Distinguish an administrative address change from an actual transfer of processing or storage. Use the differences to decide what additional evaluation or confirmatory testing is appropriate, and document which previous conclusions remain justified rather than transferring the supplier rating unchanged.
Q.When can results from different analytical methods be meaningfully compared in a trend review?+
Common analytical practice is to compare results only after establishing comparable measurands, units, moisture basis, toxin-total definitions, and treatment of results below reporting limits. Assess matrix suitability, extraction recovery, reporting sensitivity, and measurement uncertainty for each method. Paired testing of representative material can help identify method-related bias. During an out-of-trend review, mark method changes explicitly and keep separate series where comparability remains unresolved; an apparent shift may reflect the measurement system rather than ingredient quality.
Q.What evidence helps assess inventory already used when a supplier later corrects a COA associated with [incoming verification](/glossary/supplier-coa-verification-supplement)?+
A practical impact assessment preserves the original and corrected certificates, the supplier's explanation, underlying laboratory reports, and any independent results. Establish whether the correction changes a concentration, unit, reporting basis, sample identity, or acceptance conclusion. Trace affected receipts through dispensing, batch execution history, remaining stock, and distributed product. Reconstruct decisions using the specification effective at the time. Quality personnel can then assess affected batches and disposition options against the corrected evidence, documenting uncertainties and the reasoning for action.
Primary sources
Want to see how Mycotoxin Control (Supplements) could fit into your own records and workflows? Explore the related V5 pages or talk to our team about what applies to your operation.
